Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3b, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia in Subjects Hospitalized for Acute Exacerbation

Next Previous
Trial Profile

A Phase 3b, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia in Subjects Hospitalized for Acute Exacerbation

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aripiprazole lauroxil (Primary) ; Aripiprazole; Paliperidone
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Acronyms ALPINE
  • Sponsors Alkermes plc

    • Most Recent Events

    • 11 Sep 2023 According to a Alkermes media release, result of post-hoc analysis of this trial, presented at the 36th Annual Psych Congress (Psych Congress), which took place Sept. 6-10, 2023 in Nashville.
    • 20 Apr 2021 According to an Alkermes plc media release, results of exploratory analyses from the study have been presented at the virtual 2021 Congress of the Schizophrenia International Research Society (SIRS).
    • 14 Sep 2020 According to an Alkermes media release, data from this study was presented at the Psych Congress 2020 Virtual Experience, held Sept. 10-13, 2020.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top